Entity Details

Primary name IMDH1_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP20839
EntryNameIMDH1_HUMAN
FullNameInosine-5'-monophosphate dehydrogenase 1
TaxID9606
Evidenceevidence at protein level
Length514
SequenceStatuscomplete
DateCreated1991-02-01
DateModified2021-06-02

Ontological Relatives

GenesIMPDH1

GO terms

Show/Hide Table
GOName
GO:0000166 nucleotide binding
GO:0003676 nucleic acid binding
GO:0003677 DNA binding
GO:0003723 RNA binding
GO:0003938 IMP dehydrogenase activity
GO:0005576 extracellular region
GO:0005634 nucleus
GO:0005737 cytoplasm
GO:0005829 cytosol
GO:0006177 GMP biosynthetic process
GO:0006183 GTP biosynthetic process
GO:0009168 purine ribonucleoside monophosphate biosynthetic process
GO:0034774 secretory granule lumen
GO:0035578 azurophil granule lumen
GO:0042802 identical protein binding
GO:0043312 neutrophil degranulation
GO:0046872 metal ion binding
GO:1904813 ficolin-1-rich granule lumen

Subcellular Location

Show/Hide Table
Subcellular Location
Cytoplasm
Nucleus

Domains

Show/Hide Table
DomainNameCategoryType
IPR000644 CBS domainDomainDomain
IPR001093 IMP dehydrogenase/GMP reductaseDomainDomain
IPR005990 Inosine-5'-monophosphate dehydrogenaseFamilyFamily
IPR013785 Aldolase-type TIM barrelFamilyHomologous superfamily
IPR015875 IMP dehydrogenase / GMP reductase, conserved siteSiteConserved site

Diseases

Show/Hide Table
Disease IDSourceNameDescription
613837 OMIMLeber congenital amaurosis 11 (LCA11)A severe dystrophy of the retina, typically becoming evident in the first years of life. Visual function is usually poor and often accompanied by nystagmus, sluggish or near-absent pupillary responses, photophobia, high hyperopia and keratoconus. The disease is caused by variants affecting the gene represented in this entry.
180105 OMIMRetinitis pigmentosa 10 (RP10)A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. The disease is caused by variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB00157 NADHDrugbanksmall molecule
DB00688 Mycophenolate mofetilDrugbanksmall molecule
DB00811 RibavirinDrugbanksmall molecule
DB00993 AzathioprineDrugbanksmall molecule
DB01024 Mycophenolic acidDrugbanksmall molecule
DB01033 MercaptopurineDrugbanksmall molecule
DB03948 6-Chloropurine Riboside, 5'-MonophosphateDrugbanksmall molecule
DB06103 VX-148Drugbanksmall molecule
DB06408 TaribavirinDrugbanksmall molecule